... Genetics (MYGN): MYGN is moved to Outperform from Sector Perform at RBC Capital, which establishes a $23 target price on their view that expectations are low and fiscal 2011 estimates achievable. Allstate (ALL): The stock is added to …
Meanwhile, Myriad Genetics /quotes/zigman/58124 /quotes/nls/mygn MYGN was one of the few that did manage to buck the tide, rising nearly 2% after notes from other firms in the field concluded that synthetic DNA could be patentable. The …
Myriad Genetics Inc. MYGN reported adjusted earnings per share (EPS ... It has a four-quarter average earnings surprise of 8.45%. Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
MYRIAD GENETICS INC (NASDAQ:MYGN) - Myriad Genetics, Inc., a molecular diagnostic ... in all US stocks and …
Highlighted stocks include: Myriad Genetics (Nasdaq: MYGN), Onyx Pharmaceuticals Inc. (Nasdaq ... As a PhD in …
Myriad Genetics, Inc. MYGN is scheduled to report third-quarter fiscal 2017 ... show that Myriad Geneticsis likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 …
The stock has “Buy” rating by Stifel Nicolaus on Thursday, July 30. Springbok Capital Management Llc decreased …
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and …